Roughly 70% of healthcare decisions depend on laboratory test results, according to the CDC. That single number captures why tests hold such an outsized role in medicine: they are the foundation for nearly every diagnosis, treatment plan, and follow-up decision your doctor makes. But the importance of testing extends well beyond the exam room, influencing everything from how early a disease is caught to whether a medication will work safely in your body.
Early Detection Changes Survival Odds
The clearest case for testing is what happens when diseases are found early versus late. Overall cancer mortality in the United States dropped 25% between 1990 and 2015, and a significant share of that decline traces back to screening programs. Colorectal cancer mortality fell 47% among men and 44% among women over that period. Breast cancer mortality fell 39% among women. These aren’t small gains. They represent millions of people who survived because a routine test flagged something before symptoms appeared.
The pattern holds across cancer types, though not equally. Ovarian cancer, which is harder to screen for, still saw its five-year survival rate climb from about 34% in 1975 to 46% by 2008. That improvement came partly from better treatments, but also from catching cases at earlier, more treatable stages. The principle is straightforward: the sooner you know about a problem, the more options you have and the better those options tend to work.
Monitoring Keeps Chronic Conditions in Check
For people living with a chronic condition like diabetes, testing isn’t a one-time event. It’s an ongoing feedback loop. Regular blood sugar monitoring, particularly through a marker that reflects your average blood sugar over the past two to three months, helps you and your doctor see whether your management plan is working or needs adjustment.
Research published in BMJ Open Diabetes Research & Care showed that people with diabetes who spent less time with their blood sugar levels in a healthy target range faced higher risks of both small-vessel complications (like kidney and eye damage) and large-vessel complications (like heart disease and peripheral artery problems). Patients whose levels stayed in range less than 20% of the time had up to an 8% higher risk of developing cardiovascular complications compared to those who maintained their target more than 80% of the time. The study also found that kidney disease, cardiovascular problems, and blood vessel damage in the limbs all progressed faster when levels drifted outside the target range. Consistency matters as much as the average number itself, and only regular testing reveals whether that consistency exists.
Tests Drive the Majority of Medical Decisions
It’s easy to think of a blood draw or urine sample as a minor step in a doctor’s visit, but those results carry enormous weight. When roughly seven out of ten clinical decisions hinge on lab work, the accuracy and availability of tests shape virtually every aspect of patient care. A single blood panel can reveal infections, organ function, nutritional deficiencies, hormone imbalances, and markers of inflammation, all at once.
This reliance on testing also means the quality of those tests matters enormously. Every diagnostic test involves a tradeoff between two properties: how well it catches people who actually have a condition, and how well it correctly clears people who don’t. Lowering the threshold for a positive result catches more true cases but also flags more healthy people unnecessarily. Raising it reduces false alarms but risks missing real disease. Doctors weigh these tradeoffs differently depending on the stakes. For a condition where missing a case could be fatal, they lean toward casting a wider net, even if it means some extra follow-up tests for people who turn out to be fine.
Genetic Testing Prevents Drug Reactions
One of the newer frontiers in testing involves checking your genes before prescribing certain medications. Over 90% of people carry at least one genetic variant that would change how their body processes a commonly prescribed drug. That’s not a rare edge case. It’s the norm.
Your genes influence how quickly your liver breaks down medications, which determines whether a standard dose is too weak, just right, or dangerously strong for you. Someone who metabolizes a drug slowly can end up with toxic levels in their bloodstream at a dose that works perfectly for someone else. Conversely, someone who metabolizes a drug too quickly may never get enough of the active compound to benefit from it. A simple genetic test before starting treatment can flag these mismatches.
The real-world impact is measurable. In clinical studies, using genetic information to guide prescribing decisions reduced adverse drug reactions by 25% compared to standard care. One early success story involved a medication used to treat HIV. Before genetic screening was introduced, 5 to 8% of patients developed a serious hypersensitivity reaction within weeks of starting the drug. Pre-treatment testing now identifies patients at risk and steers them toward alternatives, effectively eliminating those reactions. Similar approaches are used for certain cancer chemotherapy drugs, where identifying patients with a genetic vulnerability allows doctors to reduce the dose and avoid severe toxicity.
Testing Protects Entire Communities
Individual tests serve individual patients, but testing at scale protects populations. During infectious disease outbreaks, the speed at which laboratories can confirm cases determines how quickly public health officials can respond. When COVID-19 emerged, Canada’s national laboratory developed molecular diagnostic methods that confirmed the country’s first case in January 2020, weeks before the virus was widespread. That early confirmation triggered contact tracing, quarantine measures, and surveillance systems that slowed initial spread.
Standardized testing also makes it possible to track how an outbreak is evolving across different regions. Without consistent lab-confirmed case definitions, comparing infection rates between cities or countries becomes unreliable, and resources get misallocated. Rapid, accurate diagnostic testing is the infrastructure that turns scattered case reports into a coherent picture of a threat.
New Treatments Depend on Rigorous Testing
Before any medication, vaccine, or medical device reaches you, it passes through a structured series of tests designed to answer increasingly difficult questions. The first phase of clinical trials establishes basic safety in a small group of people: does this cause immediate harm? The second phase expands the group and begins looking for evidence that the treatment actually works. The third phase enrolls large numbers of participants to confirm that the benefits outweigh the risks in a precisely defined group of patients. Even after a treatment is approved, a fourth phase of testing continues to monitor for rare but serious side effects that smaller studies couldn’t detect.
This layered approach exists because some problems only become visible at scale. A side effect that occurs in 1 out of 10,000 patients won’t show up in a trial of 500 people. Post-approval testing catches these signals and, when necessary, leads to updated warnings, dosage changes, or withdrawal of a product from the market.
Prevention Costs Less Than Treatment
Testing also makes financial sense. The CDC uses cost-effectiveness analyses to compare the expense of preventive screening against the cost of treating disease that goes undetected. In one example, a chlamydia screening program for high-risk women cost about $23,800 to implement but prevented over 10 cases of pelvic inflammatory disease, a serious complication that would have cost roughly $13,000 to treat. The net cost worked out to about $1,020 per case of disease prevented, a modest investment to avoid pain, hospitalization, and potential infertility.
Some preventive testing programs don’t just reduce costs per case. They save money outright. The childhood vaccination program in the United States, which relies on testing at every stage of vaccine development and quality control, produces an estimated $68.9 billion in net savings when medical costs and lost productivity are factored in. The math isn’t always this dramatic, but the direction is consistent: catching problems early or preventing them entirely costs less than treating them after they’ve progressed.